Drug intelligence / Profile preview

huaizhen Yanggan capsule

Development stage: Preclinical
Lead developer: Shuguang Hospital
Modality: Small Molecules
Administration: Oral

Overview

Huaizhen Yanggan capsule is a Traditional Chinese Medicine (TCM) therapeutic developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine for the treatment of knee osteoarthritis. Based on TCM principles, the formulation is designed to "nourish the liver" (Yanggan), a strategy employed because the liver is traditionally viewed as the regulator of tendons and ligaments. By strengthening these tissues and potentially exerting anti-inflammatory effects, the capsule aims to reduce pain and improve mobility in patients suffering from degenerative joint disease. It is currently being evaluated in clinical trials to establish its efficacy and safety profile.

Brand names: huaizhen yanggan capsule
Other names: Huaizhen Yanggan capsule

Beyond the preview

Go deeper on huaizhen Yanggan capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on huaizhen Yanggan capsule.

Explore the full profile